UCB Presents Nine Abstracts at EADV 2020, Showcasing Ongoing Commitment to Dermatology.

Brussels, Belgium – October 29, 2020 – UCB, a global biopharmaceutical company, today announced that new data on the investigational IL-17A and IL-17F inhibitor, bimekizumab, and TNF inhibitor, CIMZIA ® (certolizumab pegol), in the management of moderate-to-severe plaque psoriasis are being presented at the European Academy of Dermatology and Venereology (EADV) Congress, taking place virtually on October 29- 31, 2020. The first presentation of the Phase 3 BE SURE study results demonstrates the superior levels of psoriasis skinclearance observed with bimekizumab treatment, as compared to...